The share of the Swedish medtech company Elekta, which manufactures radiation equipment for cancer treatment, was up this Tuesday after Goldman Sachs added it to its list of preferred shares and resumed coverage.
Goldman Sachs sees Elekta as the strongest share in the European medtech industry, according to a new analysis from the American bank. The reason is a high demand on radiation treatment, for which the bank estimates a market growth of 6 % a year from 2012 to 2017.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app